Form 4: Vir Bio Director Sells 22,000 Shares via 10b5-1 Plan

Vir Biotechnology Director Vicki L. Sato sold 22,000 shares of common stock for approximately $6.00 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Vicki L. Sato, a Director at Vir Biotechnology, Inc. (VIR), reported the sale of 22,000 shares of common stock.
• The transaction occurred on December 1, 2025.
• The shares were sold at a weighted average price of $6.0032 per share, with individual transaction prices ranging from $5.87 to $6.23.
• Following this transaction, Ms. Sato beneficially owns 1,188,391 shares of Vir Biotechnology common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Ms. Sato on March 27, 2025.

Sentiment

Score: 5

Explanation: Neutral. While an insider sale can be seen as negative, the fact that it was executed under a pre-arranged 10b5-1 plan mitigates much of the negative sentiment, indicating a planned financial event rather than a reaction to new, adverse information.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned transaction rather than a reaction to new, non-public information.

Negatives

• A director selling a significant number of shares, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces insider ownership.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing.

Industry Context

Insider sales, even pre-planned, are common in the biotechnology industry, where executives often have significant equity compensation. The impact depends on the size of the sale relative to total holdings and the company's recent performance.

Comparison to Industry Standards

• Insider sales are a routine occurrence across all industries, including biotechnology.
• The use of a Rule 10b5-1 plan is a standard practice for insiders to sell shares systematically while avoiding accusations of trading on material non-public information. Many executives at companies like Pfizer, Moderna, and Gilead Sciences utilize such plans for personal financial planning.
• The sale of 22,000 shares by a director, while notable, needs to be viewed in the context of the director's remaining holdings of over 1.1 million shares, suggesting it's a relatively small portion of their overall stake.

Stakeholder Impact

• Shareholders: May interpret the sale as a slight negative signal, though the 10b5-1 plan reduces this concern. The reduction in insider ownership is minimal relative to total holdings.

Key Dates

Recommendation

The Form 4 filing reports a pre-planned sale by a director under a 10b5-1 plan. This type of transaction is generally for personal financial management and does not typically signal a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this filing. The sale represents a small portion of the director's overall holdings.

Keywords

Vir Biotechnology, VIR, Vicki L. Sato, Insider Sale, Form 4, 10b5-1 Plan, Director Transaction, Stock Sale